Thiazolidinedione derivatives and pharmaceutical composition...

Details Thiazolidinedione derivatives and pharmaceutical composition... Thiazolidinedione derivatives and pharmaceutical composition...

2003-07-03

2004-09-07

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S269000, C514S342000, C544S326000, C544S327000, C546S269700

Reexamination Certificate

active

06787551

ABSTRACT:

TECHNICAL FIELD
The present invention relates to a thiazolidinedione derivative, represented in formula (1) below, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof. Further, the present invention provides a pharmaceutical composition comprising the compound represented in formula (1) below.
wherein:
X represents a carbon or nitrogen atom; Y represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen, or an aryl group; Z represents an oxygen, nitrogen, or sulfur atom; and R
1
and R
2
each represent a hydrogen atom, or R
1
and R
2
together form a bond.
BACKGROUND ART
Thiazolidinedione based compounds are oral diabetes therapeutic agents for treating insulin resistance, using a new mechanism different from that of conventional diabetes therapeutic agents. They lower blood sugar level by increasing physiological effects of insulin on target cells (muscle, adipocytes, liver, etc.). Now, the thiazolidinedione based compounds are highlighted as new diabetes therapeutic agents. Further, it has been reported in several documents that as insulin, free fatty acid, and triglyceride, etc. accumulate to high levels in the body, the thiazolidinedione based compounds strongly suppress further synthesis (Miuoru Oguchi, et al.,
J.Med. Chem
., 2000, 43, 3052-3066; B. B. Lohray, et al.,
J. Med. Chem
., 1999, 42, 2569-2581; Braj. B. Lohray, V. Bhushan, et al.,
Bioorg. Med. Chem. Lett
., 1997, 7(7), 785-788; Kelving. Liu, et al.,
Bioorg. Med. Chem. Lett
., 2001, 11, 2385-2388; T. M. Willson et al.,
J. Med. Chem
., 2000, 43(4), 527-550; Jeffery, E. Cobb, et al.,
J. Med. Chem
., 1996, 39, 665-668
; J. Med. Chem
., 1998, 41, 5055-5069; John L. Collins, et al.,
J. Med. Chem
., 1998, 41, 5037-5054; Hisashi Shinkai et al.,
J. Med. Chem
., 1998, 41, 1927-1933).
Rosiglitazone is commercially available. It is the strongest thiazolidinedione based compound discovered until now. It has been disclosed in European Patent Laid-Open Publication No. 0,842,925 and a journal (J. Med. Chem., 1994, 37, 3977-3985), which are incorporated herein by reference.
Rosiglitazone, having a structure similar to that of the present invention, is represented in formula (2) below.
wherein, A
1
is formula (a) or (b) below:
wherein, R
4
and R
5
each independently represent a hydrogen atom, an alkyl group or a substituted or unsubstituted aryl group, or when R
4
and R
5
are each attached to adjacent carbons, R
4
and R
5
together with the carbon atoms to which they are attached form a benzene ring, in which each carbon atom represented by R
4
and R
5
together may be substituted or unsubstituted.
Rosiglitazone exhibits a moderate blood sugar-lowering effect, but has little activity versus hyperlipidemia, which is common in patients with diabetes. Furthermore, because its half life is short in terms of pharmacodynamics, it must be inconveniently administered twice a day. In rare cases, it has been clinically reported that liver toxicity involved in use of rosiglitazone drugs causes death. Therefore, there is a disadvantage in that the patients with diabetes must have their liver function tested periodically.
DISCLOSURE OF THE INVENTION
Therefore, the present invention has been made in view of the above problems, and it is an object of the present invention to provide a new thiazolidinedione based compound having activities such as strong blood sugar lowering action and strong blood lipid lowering action, compared with rosiglitazone, and a pharmaceutical composition containing the thiazolidinedione based compound.
It is another object of the present invention to provide a new thiazolidinedione based compound, in which its half-life is remarkably prolonged, and a pharmaceutical composition containing the thiazolidinedione based compound.
It is yet another object of the present invention to provide a new thiazolidinedione based compound, in which liver toxicity, a common side effect encountered with this type of compound drug, is not found, and a pharmaceutical composition containing the thiazolidinedione based compound.


REFERENCES:
patent: 5441971 (1995-08-01), Sohda et al.
patent: 5708012 (1998-01-01), Olefsky
patent: 0842925 (1998-05-01), None
patent: 98-55121 (1998-12-01), None
Gurram R. Madhavan, et al., “Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents” In European Journal of Medicinal Chemistry, vol. 36, 2001, p. 627-37.
Miuoru Oguchi, et al.,J. Med. Chem., 2000, 43, 3052-3066.
B.B. Lohray, et al.,J. Med. Chem., 1999, 42, 2569-2581.
Braj. B. Lohray, V. Bhushan, et al.,Bioorg. Med. Chem. Lett., 1997, 7(7), 785-788.
Kelving. Liu, et al.,Bioorg. Med. Chem. Lett., 2001, 11, 2385-2388.
T. M. Willson et al.,J. Med. Chem., 2000, 43(4), 527-550.
Jeffrey. E. Cobb, et al.,J. Med. Chem., 1996, 39, 665-668.
J. Med. Chem., 1998, 41, 5055-5069.
John L. Collins, et al.,J. Med. Chem., 1998, 41, 5037-5054.
Hisashi Shinkai et al.,J. Med. Chem., 1998, 41, 1927-1933.

Affiliated with

Also associated with

Rating

Thiazolidinedione derivatives and pharmaceutical composition... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thiazolidinedione derivatives and pharmaceutical composition..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiazolidinedione derivatives and pharmaceutical composition... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3254120